Total Payments
$369,644
2024 Payments
$89,624
Companies
21
Transactions
311
Medicare Patients
337
Medicare Billing
$39,394
Payment Breakdown by Category
Consulting$254,164 (68.8%)
Other$65,024 (17.6%)
Travel$39,263 (10.6%)
Food & Beverage$10,516 (2.8%)
Education$677.97 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $254,164 | 62 | 68.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $48,865 | 16 | 13.2% |
| Travel and Lodging | $39,263 | 89 | 10.6% |
| Honoraria | $16,159 | 3 | 4.4% |
| Food and Beverage | $10,516 | 129 | 2.8% |
| Education | $677.97 | 12 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $89,717 | 47 | $0 (2024) |
| GENZYME CORPORATION | $74,452 | 45 | $0 (2024) |
| Genentech USA, Inc. | $52,258 | 54 | $0 (2024) |
| CSL Behring | $44,856 | 42 | $0 (2024) |
| Shire North American Group Inc | $39,705 | 53 | $0 (2019) |
| F. Hoffmann-La Roche AG | $15,363 | 6 | $0 (2020) |
| PFIZER INC. | $13,343 | 11 | $0 (2024) |
| BIOVERATIV THERAPEUTICS INC. | $12,804 | 18 | $0 (2019) |
| Gilead Sciences Inc | $7,595 | 4 | $0 (2017) |
| Spark Therapeutics, Inc. | $5,014 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $89,624 | 53 | GENZYME CORPORATION ($42,959) |
| 2023 | $41,782 | 35 | GENZYME CORPORATION ($18,507) |
| 2022 | $26,728 | 25 | Novo Nordisk Inc ($10,770) |
| 2021 | $25,199 | 26 | Novo Nordisk Inc ($9,668) |
| 2020 | $22,796 | 9 | CSL Behring ($6,104) |
| 2019 | $50,982 | 46 | Novo Nordisk Inc ($18,885) |
| 2018 | $49,380 | 35 | CSL Behring ($12,444) |
| 2017 | $63,152 | 82 | Shire North American Group Inc ($19,183) |
All Payment Transactions
311 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | PFIZER INC. | HYMPAVZI (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $138.14 | General |
| 12/06/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 12/06/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $128.91 | General |
| 11/22/2024 | CSL Behring | HEMGENIX (Biological) | Consulting Fee | Cash or cash equivalent | $6,695.00 | General |
| Category: Hematology | ||||||
| 11/21/2024 | PFIZER INC. | BENEFIX (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: HEMATOLOGY | ||||||
| 11/12/2024 | CSL Behring | HEMGENIX (Biological) | Travel and Lodging | In-kind items and services | $277.00 | General |
| Category: Hematology | ||||||
| 11/12/2024 | CSL Behring | HEMGENIX (Biological) | Travel and Lodging | In-kind items and services | $253.80 | General |
| Category: Hematology | ||||||
| 11/12/2024 | CSL Behring | HEMGENIX (Biological) | Travel and Lodging | In-kind items and services | $253.80 | General |
| Category: Hematology | ||||||
| 11/12/2024 | CSL Behring | HEMGENIX (Biological) | Food and Beverage | In-kind items and services | $40.16 | General |
| Category: Hematology | ||||||
| 11/12/2024 | CSL Behring | HEMGENIX (Biological) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: Hematology | ||||||
| 11/12/2024 | CSL Behring | HEMGENIX (Biological) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Hematology | ||||||
| 11/12/2024 | CSL Behring | HEMGENIX (Biological) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: Hematology | ||||||
| 11/12/2024 | CSL Behring | HEMGENIX (Biological) | Food and Beverage | In-kind items and services | $6.46 | General |
| Category: Hematology | ||||||
| 11/01/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $9,371.25 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $349.53 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $334.12 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $281.37 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $265.88 | General |
| 10/24/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,888.00 | General |
| Category: Hematology | ||||||
| 10/24/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,136.00 | General |
| Category: Hematology | ||||||
| 10/24/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | In-kind items and services | $441.57 | General |
| Category: Hematology | ||||||
| 10/24/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | In-kind items and services | $422.15 | General |
| Category: Hematology | ||||||
| 09/06/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Consulting Fee | Cash or cash equivalent | $6,460.00 | General |
| Category: Hematology | ||||||
| 09/06/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $170.20 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 76 | 94 | $34,240 | $8,908 |
| 2022 | 3 | 95 | 113 | $43,040 | $11,010 |
| 2021 | 4 | 107 | 121 | $54,440 | $13,025 |
| 2020 | 3 | 59 | 69 | $29,160 | $6,451 |
Total Patients
337
Total Services
397
Medicare Billing
$39,394
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 36 | 38 | $20,520 | $4,827 | 23.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 17 | $7,480 | $2,216 | 29.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 24 | 39 | $6,240 | $1,865 | 29.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 45 | 48 | $25,920 | $6,510 | 25.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 16 | $9,280 | $2,653 | 28.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 34 | 49 | $7,840 | $1,846 | 23.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 45 | 45 | $24,300 | $5,716 | 23.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 20 | 23 | $13,340 | $3,467 | 26.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $10,400 | $2,421 | 23.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 29 | 40 | $6,400 | $1,421 | 22.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 28 | 30 | $16,200 | $3,588 | 22.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 16 | $9,280 | $2,018 | 21.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 17 | 23 | $3,680 | $845.05 | 23.0% |
About Dr. Christopher Walsh, MD
Dr. Christopher Walsh, MD is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588694095.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Walsh, MD has received a total of $369,644 in payments from pharmaceutical and medical device companies, with $89,624 received in 2024. These payments were reported across 311 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($254,164).
As a Medicare-enrolled provider, Walsh has provided services to 337 Medicare beneficiaries, totaling 397 services with total Medicare billing of $39,394. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 07/03/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1588694095
Products in Payments
- HEMLIBRA (Biological) $44,626
- ALTUVIIIO (Biological) $28,139
- Idelvion (Biological) $27,174
- HEMGENIX (Biological) $15,432
- Hemlibra (Biological) $13,459
- ADVATE (Biological) $12,167
- ADYNOVATE (Biological) $9,443
- Non-Covered Product (Drug) $8,922
- NovoSeven RT (Drug) $7,158
- NO PRODUCT DISCUSSED (Drug) $5,539
- ELOCTATE (Biological) $4,555
- Rebinyn (Biological) $4,463
- Alphanate (Biological) $4,167
- HYMPAVZI (Drug) $3,000
- BENEFIX (Biological) $2,750
- Koate (Drug) $2,500
- Afstyla (Biological) $2,250
- Esperoct (Biological) $1,890
- ROCTAVIAN (Drug) $205.42
- Alprolix (Drug) $153.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205